Vanda Pharmaceuticals Inc.'s jet lag disorder drug Hetlioz has been accepted by the U.S. Food and Drug Administration for review.

The agency has set a date of Aug. 16, 2019, for completing its review, according to Vanda's Dec. 20 press release.

Hetlioz is already approved for treating non-24 hour sleep-wake disorder and is in clinical trials for symptoms of a rare disorder called Smith-Magenis syndrome.

Washington, D.C.-based Vanda is a biopharmaceutical company that develops products to treat central nervous system disorders.